Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Boehringer Ingelheim International Gmbh

The Broad Institute, Inc.

Damian Brockschnieder

Frank Wunder

Tobias Marquardt

Johannes-Peter Stasch

Alexandros Vakalopoulos

Volkhart Min-Jian Li

Lisa Dietz

Dmitry Zubov

Dieter Lang

Adrian Tersteegen

Markus Follmann

Gorden Redlich

Martina Schäfer

Thomas Neubauer

Jan Tebbe

Carsten Terjung

Alexey Gromov

Andreas Wilmen

Florian Kölling

Hideki Miyatake Ondozabal

Nicole Biber

Jörg Meding

Min Jian Volkhart Li

Pierre Wasnaire

Klemens Lustig

Heinrich Meier

Niels Lindner

Yolanda Cancho Grande

Simone Greven

Christoph Mahlert

Thomas Mondritzki

Sarah Anna Liesa Johannes

Ernst Weber

Kersten Matthias Gericke

Dieter Moosmayer

Ilka Mathar

Till Freudenberger

Volker Badock

Lucas Hudson Hofmeister

Andreas Timmermann

Hannah Jörissen

Claudia Noack

Marcel Geertz

Stuart Walsh

Anke Mayer-bartschmid

Guzman Sanchez

Nadine Elowe

Tanja Krainz

Yi Xing

Bryan Macdonald

Dzianis Menshykau

Kristin Beyer

Alexander Schulz

Stephen Moore

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. Ris hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; Ris hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R, R, R, R, Rand Rare independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R, R, Ris H; X, X, X, X, Xand Xare independently N or C; with the proviso that in each ring maximal one X is N.

Substituted hydantoinamides as ADAMTS7 antagonists

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Ntls), a Brain Natriuretic Peptide (BNP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Brain natriuretic peptide engrafted antibodies

The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.

Atrial natriuretic peptide engrafted antibodies

The invention relates to prolyl endopeptidase (PREP) inhibitors of formula (I) which contain a condensed 2,4-dihydro-3H-1,2,4-triazol-3-one ring system, methods for producing same, the use thereof alone or in combinations for treating and/or preventing diseases, and the use thereof for producing drugs for treating and/or preventing diseases, in particular for treating and/or preventing inflammatory lung diseases (COPD). 

Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors

The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders. 

Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereof

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Heteroaryl-substituted imidazo[1,2-A]pyridines and their use

The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof

The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-A]pyridines and their use

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases

The present application relates to novel 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines

The present application relates to novel benzyl-1H-pyrazolo[3,4-b]pyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof

Growing community of inventors

Haan, Germany

Damian Brockschnieder